Bicycle Therapeutics to Present Urothelial Carcinoma Data at ASCO 2026
Event summary
- Bicycle Therapeutics will present oral and poster data at the ASCO 2026 Annual Meeting, June 1-2 in Chicago.
- Key data focuses on zelenectide pevedotin (BT8009) in combination with pembrolizumab and as a monotherapy for urothelial carcinoma.
- An oral presentation will detail interim analysis results from the Duravelo-2 trial.
- The presentations will be made available on Bicycle Therapeutics' website starting May 31, 2026.
The big picture
Bicycle Therapeutics is attempting to establish a foothold in the crowded immuno-oncology space with its unique bicyclic peptide technology. The ASCO presentations represent a crucial inflection point for the company, as the data will directly impact the perceived viability of its lead asset, zelenectide pevedotin, and its broader pipeline strategy. Success here could validate the BDC platform, while negative results could significantly impact the company's valuation.
What we're watching
- Clinical Efficacy
- The oral presentation’s interim analysis results will be critical in assessing the potential of zelenectide pevedotin in combination with pembrolizumab, and will likely influence investor sentiment regarding the Duravelo-2 trial’s overall success.
- Monotherapy Potential
- The updates on Duravelo-1 will reveal whether zelenectide pevedotin demonstrates sufficient efficacy as a monotherapy, which could broaden its potential market and reduce reliance on combination therapies.
- Dosage Optimization
- The poster detailing dosage optimization efforts will provide insight into Bicycle Therapeutics' ability to refine the therapeutic window of zelenectide pevedotin and mitigate potential toxicity concerns.
Related topics